07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

ADI-PEG 20: Phase Ib data

Top-line data from an open-label, U.S. Phase Ib trial in 18 patients with metastatic pancreatic cancer showed that once-weekly intramuscular ADI-PEG 20 plus gemcitabine and Abraxane nab-paclitaxel led to a disease control rate (DCR)...
07:00 , Jun 8, 2015 |  BioCentury  |  Product Development

Out with the old

Data presented at the American Society of Clinical Oncology meeting in Chicago in previously treated multiple myeloma offer the tantalizing prospect that new regimens could move up to supplant Velcade bortezomib as standard of care...
07:00 , Apr 28, 2014 |  BioCentury  |  Emerging Company Profile

Aeglea: Old enzymes, new tricks

Aeglea BioTherapeutics Holdings LLC is developing enzymes to starve tumors that depend on outside sources of specific amino acids. Aeglea's engineered human enzymes may offer lower immunogenicity and greater activity than natural versions further along...
07:00 , Oct 20, 2003 |  BioCentury  |  Emerging Company Profile

Phoenix: A better enzyme

Phoenix Pharmacologics Inc. is trying to expand the uses of two clinically validated enzymatic therapy concepts. The company's lead product, recombinant pegylated arginine deiminase (ADI-PEG 20), applies the concept behind the anti-cancer enzyme therapy asparaginase...